All News

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

Post-traumatic headaches and trigeminal autonomic cephalalgia significantly increased the risk for attempted and completed suicide, according to new study.

An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

Your daily dose of the clinical news you may have missed.

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.

Your daily dose of the clinical news you may have missed.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Your daily dose of the clinical news you may have missed.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.